Tricuspid Regurgitation
1
Pipeline Programs
3
Companies
5
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
AbbottABBOTT PARK, IL
3 programs1
EchoPhase 41 trial
The TriClip SystemN/A1 trial
TriClipTM DeviceN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
AbbottEcho
AbbottThe TriClip System
Versa VascularVersa Implant
TRiCaresTopaz TTVR System
AbbottTriClipTM Device
Clinical Trials (5)
Total enrollment: 2,901 patients across 5 trials
Tricuspid Regurgitation Study
Start: May 2010Est. completion: May 2016119 patients
Phase 4Completed
TriClip CED RWE Study
Start: Jul 2025Est. completion: Jul 20322,200 patients
N/ARecruiting
A First in Human Study for the Versa Device for Tricuspid Regurgitation
Start: Aug 2024Est. completion: Oct 202510 patients
N/AActive Not Recruiting
The TRICURE First in Human Trial
Start: Jul 2022Est. completion: May 2029
N/AActive Not Recruiting
TRILUMINATE Pivotal Trial
Start: Aug 2019Est. completion: Apr 2029572 patients
N/AActive Not Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 2,901 patients
3 companies competing in this space